Börskollen
Pressmeddelanden från ViroGates
26 mar 15:10
ViroGatesViroGates announces its Annual Report 2025: Revenue growth and improved operating result as strategic transition towards preventive health and longevity continues12 dec 2025 12:15ViroGatesViroGates publishes its financial calendar for 202612 dec 2025 11:33ViroGatesViroGates announces financial guidance for 202628 nov 2025 15:39ViroGatesViroGates’ capital raise of DKK 19.3 million and issue of 1,547,412 shares have been registered and settled20 nov 2025 14:30ViroGatessuPAR Remedy, LLC announces the Completion of the public tender offer to the shareholders of ViroGates.18 nov 2025 07:41ViroGatesViroGates announces a directed issue of nominally 1,547,412 shares, raising approximately DKK 19.3 million17 nov 2025 23:31ViroGatesViroGates announces a plan to offer new shares through a directed issue without preemptive rights for existing shareholders12 nov 2025 08:40ViroGatessuPAR Remedy, LLC announces the outcome of the Public Tender Offer to the shareholders of ViroGates.06 nov 2025 13:34ViroGatesViroGates announces its Interim Report for Q1-Q3 202523 okt 2025 15:29ViroGatesViroGates announces Notice of Potential Equity / Capital Raise17 okt 2025 14:36ViroGatesViroGates Receives FDA Feedback on 513(g) Request, confirming Regulatory Pathway for U.S. Market Entry15 okt 2025 15:22ViroGatesViroGates announces the publication of a Board Statement in relation to the Tender Offer from suPAR Remedy, LLC10 okt 2025 08:52ViroGatesViroGates announces the receipt of an Announcement and Official Tender Offer Document from suPAR Remedy LLC08 okt 2025 08:53ViroGatessuPAR Remedy, LLC announces public tender offer to the shareholders of ViroGates A/S at a 40% premium21 aug 2025 11:25ViroGatesViroGates announces its Half-Year Report for H1 202516 jun 2025 15:30ViroGatesViroGates and GENSPEED achieve proof of concept for their suPARnostic® POC+ targeted at the Longevity Testing Market21 maj 2025 16:16ViroGatesResolutions from the Extraordinary General Meeting of ViroGates A/S06 maj 2025 11:55ViroGatesViroGates gives notice to convene an Extraordinary General Meeting on 21 May 202501 maj 2025 17:39ViroGatesViroGates announces its Q1 report for 202524 apr 2025 21:17ViroGatesResolutions from the Annual General Meeting of ViroGates A/S07 apr 2025 13:25ViroGatesNotice to convene the annual general assembly20 mar 2025 19:23ViroGatesViroGates announces its Annual Report 202419 mar 2025 18:46ViroGatesViroGates announces an amendment to its agreement with Sobi16 jan 2025 22:31ViroGatesViroGates issues warrants to key employees19 dec 2024 18:08ViroGatesViroGates publishes its financial calendar for 202519 dec 2024 17:20ViroGatesViroGates announces financial guidance for 202516 dec 2024 17:16ViroGatesViroGates announces a reorganisation of its marketing and sales department and revises its guidance for the year11 nov 2024 17:05ViroGatesViroGates’ capital raise of DKK 8.2 million and issue of 1,289,510 new shares have been registered07 nov 2024 12:05ViroGatesViroGates announces its Interim Report for Q1-Q3 2024: Revenues are disappointing, but strategic refocusing will pave the way for future growth14 okt 2024 18:37ViroGatesViroGates announces a distribution agreement with suPAR Health and a directed issue of shares to suPAR Remedy LLC15 aug 2024 12:30ViroGatesViroGates announces its half-year report for H1 2024: Revenue for the first half-year of 2024 falls behind the same period in 2023 due to lower activity among research customers17 jul 2024 14:45ViroGatesViroGates announces revised financial guidance for 2024
ViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGatesViroGates